Drug Trial Radar · NCT07419295
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
590
Planned (sponsor's estimate)
Start
Apr 23, 2026
Primary completion
Jul 27, 2029
Study completion Apr 23, 2030
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Feb 19, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for new ways to treat locally advanced or metastatic urothelial cancer (UC). Current treatments for locally advanced or metastatic UC include chemotherapy, immunotherapy, and targeted therapy. Researchers want to know if giving sacituzumab tirumotecan (sac-TMT), the trial medicine, can treat locally advanced or metastatic UC that got worse after certain treatments. The goal of this trial is to learn if people who receive sac-TMT live longer than those who receive certain non-platinum chemotherapies.
Conditions
- Bladder Cancer
Interventions
Sacituzumab tirumotecanBiological
IV infusion
VinflunineDrug
IV infusion
DocetaxelDrug
IV infusion
PaclitaxelDrug
IV infusion
Rescue medications for sacituzumab tirumotecanDrug
Participants receive rescue medication at the investigator's discretion, per approved product label. Recommended rescue medications are pegfilgrastim or equivalent, histamine-1 (H1) receptor antagonist, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent, and steroid mouthwash (dexamethasone or equivalent).
Rescue medications for chemotherapyDrug
Participants receive rescue medication at the investigator's discretion, per approved product label. Recommended rescue medications are dexamethasone or equivalent, H1 receptor antagonist, H2 receptor antagonist, and laxative.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: Up to approximately 40 months
Locations
117 sites in 17 countries. Site status is shown where the registry gives one.
Hoag Memorial Hospital Presbyterian ( Site 0814)
Newport Beach, California · Recruiting
University Of Colorado Anschutz Medical Campus ( Site 0807)
Aurora, Colorado · Recruiting
University of Colorado Health - Highlands Ranch Hospital ( Site 0847)
Highlands Ranch, Colorado · Recruiting
University of Colorado Health - Lone Tree Medical Center ( Site 0848)
Lone Tree, Colorado · Recruiting
Sibley Memorial Hospital ( Site 0849)
Washington D.C., District of Columbia · Recruiting
Emory University Hospital ( Site 0824)
Atlanta, Georgia · Recruiting
University of Chicago ( Site 0845)
Chicago, Illinois · Recruiting
Johns Hopkins University ( Site 0843)
Baltimore, Maryland · Recruiting
Dana Farber Cancer Institute ( Site 0783)
Boston, Massachusetts · Recruiting
Munson Medical Center ( Site 0812)
Traverse City, Michigan · Recruiting
Morristown Memorial Hospital ( Site 0795)
Morristown, New Jersey · Recruiting
Memorial Sloan Kettering Cancer Center ( Site 0832)
New York, New York · Recruiting
WakeMed Raleigh Campus ( Site 0811)
Raleigh, North Carolina · Recruiting
TriHealth Cancer Institute-Good Samaritan Hospital ( Site 0822)
Cincinnati, Ohio · Recruiting
University Hospitals of Cleveland Case Medical Center ( Site 0834)
Cleveland, Ohio · Recruiting
Cleveland Clinic - Ohio ( Site 0793)
Cleveland, Ohio · Recruiting
Fox Chase Cancer Center ( Site 0830)
Philadelphia, Pennsylvania · Recruiting
The West Clinic, P.C. ( Site 0791)
Germantown, Tennessee · Recruiting
Thompson Cancer Survival Center ( Site 0803)
Knoxville, Tennessee · Recruiting
Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology ( Site 0831)
Nashville, Tennessee · Recruiting
University of Utah, Huntsman Cancer Institute ( Site 0810)
Salt Lake City, Utah · Recruiting
Virginia Oncology Associates (VOA) ( Site 8002)
Norfolk, Virginia · Recruiting
Fred Hutchinson Cancer Research Center ( Site 0787)
Seattle, Washington · Recruiting
Hospital Italiano de Buenos Aires ( Site 0004)
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina · Recruiting
Asociacion de Beneficencia Hospital Sirio Libanes ( Site 0003)
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina · Recruiting
Instituto Alexander Fleming ( Site 0002)
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina · Recruiting
Instituto de Oncologia de Rosario ( Site 0005)
Rosario, Santa Fe Province, Argentina · Recruiting
Macquarie University ( Site 0031)
Macquarie, New South Wales, Australia · Recruiting
Mater Hospital Brisbane ( Site 0032)
South Brisbane, Queensland, Australia · Recruiting
CHC Montlegia Clinic ( Site 0061)
Liège, Belgium · Recruiting
Cliniques Universitaires Saint-Luc ( Site 0062)
Brussels, Bruxelles-Capitale, Region de, Belgium · Recruiting
AZ Maria Middelares ( Site 0063)
Ghent, Oost-Vlaanderen, Belgium · Recruiting
UZ Gent ( Site 0064)
Ghent, Oost-Vlaanderen, Belgium · Recruiting
Hospital Alemao Oswaldo Cruz ( Site 0101)
São Paulo, Brazil · Recruiting
ICTRIALS Pesquisa e Desenvolvimento ( Site 0107)
Curitiba, Paraná, Brazil · Recruiting
Hospital Moinhos de Vento ( Site 0102)
Porto Alegre, Rio Grande do Sul, Brazil · Recruiting
Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0110)
São José do Rio Preto, São Paulo, Brazil · Recruiting
Lakeridge Health ( Site 0122)
Oshawa, Ontario, Canada · Recruiting
Princess Margaret Cancer Centre ( Site 0123)
Toronto, Ontario, Canada · Recruiting
Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0121)
Québec, Quebec, Canada · Recruiting
Showing 40 of 117 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.